We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Disease progress in patients with Morbus Fabry after switching from agalsidase beta to agalsidase alpha.
- Authors
Reidt, S.; Namdar, M.; Serra, A.; Krayenbühl, P. A.; Gruner, C.; Keller, D. I.; Lüscher, T. F.; Schmied, C.
- Abstract
The article discusses the study regarding the disease progression in patients with Fabry disease (FD) following their switch to recombinant substance agalsidase-alpha from agalsidase-beta. The study examines 10 male patients that undergoes agalsidase-beta and agalsidase-alpha treatment in Zurich, Switzerland. Other topics discussed include enzyme-replacement therapy (ERT), drug shortage, and European Medicines Agency (EMA).
- Subjects
RECOMBINANT proteins; CLINICAL trials; CASE studies; HEALTH outcome assessment; TREATMENT effectiveness; DISEASE progression; ANGIOKERATOMA corporis diffusum; THERAPEUTICS
- Publication
Internal Medicine Journal, 2014, Vol 44, Issue 2, p205
- ISSN
1444-0903
- Publication type
Article
- DOI
10.1111/imj.12348